Quick Answer
NEKTAR THERAPEUTICS reported Net Income Loss of -$164.08 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -37.9% in Net Income Loss from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $70.61 million | Q4 2014: -$45.68 million | Q1 2015: $33.82 million | Q2 2015: -$52.66 million | Q3 2015: -$8.20 million | Q4 2015: -$54.14 million | Q1 2016: -$19.50 million | Q2 2016: -$48.60 million | Q3 2016: -$43.22 million | Q4 2016: -$42.20 million | Q1 2017: -$63.87 million | Q2 2017: -$59.87 million | Q3 2017: $60.87 million | Q4 2017: -$33.83 million | Q1 2018: -$95.79 million | Q2 2018: $971.46 million | Q3 2018: -$96.14 million | Q4 2018: -$98.21 million | Q1 2019: -$119.63 million | Q2 2019: -$110.29 million | Q3 2019: -$98.59 million | Q4 2019: -$112.16 million | Q1 2020: -$138.65 million | Q2 2020: -$80.00 million | Q3 2020: -$108.59 million | Q4 2020: -$117.20 million | Q1 2021: -$122.97 million | Q2 2021: -$125.52 million | Q3 2021: -$129.71 million | Q4 2021: -$145.65 million | Q1 2022: -$90.39 million | Q2 2022: -$159.07 million | Q3 2022: -$59.05 million | Q1 2023: -$137.02 million | Q2 2023: -$51.12 million | Q3 2023: -$45.84 million | Q1 2024: -$36.80 million | Q2 2024: -$52.36 million | Q3 2024: -$37.06 million | Q1 2025: -$50.88 million | Q2 2025: -$41.59 million | Q3 2025: -$35.52 million.
- Over the full 17 years of available data (2009 to 2025), NEKTAR THERAPEUTICS's Net Income Loss has declined by 60.0%.
- Historical annual values: Fiscal year 2025: -$164.08 million | Fiscal year 2024: -$118.96 million | Fiscal year 2023: -$276.06 million | Fiscal year 2022: -$368.20 million | Fiscal year 2021: -$523.84 million | Fiscal year 2020: -$444.44 million | Fiscal year 2019: -$440.67 million | Fiscal year 2018: $681.31 million | Fiscal year 2017: -$96.69 million | Fiscal year 2016: -$153.52 million | Fiscal year 2015: -$81.18 million | Fiscal year 2014: -$53.92 million | Fiscal year 2013: -$162.01 million | Fiscal year 2012: -$171.86 million | Fiscal year 2011: -$133.98 million | Fiscal year 2010: -$37.94 million | Fiscal year 2009: -$102.52 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: